• Participation in the CRISALIS network (Clinical Research Initiative in Severe Asthma : a Lever for Innovation & Science) or clinical investigation of severe asthma.

• Participation in the COVIREIVAC of clinical investigation network for COVID-19 vaccination

• Participation in the development of the EUCLID platform (EUropean CLInical Trials Services Platform & Development — F-CRIN infrastructures selection 2013 – Prof. G. Chêne)

• Fulbright scholarship laureate and Monahan grant in Medical Research (2012- P.O. Girodet

• Collaboration with the Asthma Research Center (Prof. Elliot Israel), Harvard Medical School, Brigham and Women Hospital, Boston, MA

• Collaboration with the Wellman Institute (Prof. Gary Tearney), Boston

• Industrial partnership

• 2022: MYCADO protocol — Environmental mycobiota: in-depth characterization and determinants involved in asthma progression

• 2022: MOTOR protocol — involvement of skeletal muscle fybrocytes in sarcopenia in COPD patients

• 2020: BENRAMOD protocol — effect of benralizumab on bronchial remodelling in asthma

• 2020: PIMABOD protocol — identification of phenotypes on multimodal MRI of the thorax of patients with obstructive bronchial diseases

•  2014: INTUITIVE protocol — descriptive study of the ability to learn to use inhalation systems in COPD

• 2014: INHALER protocol — Real-life evaluation of the handling of inhalation systems in COPD

• 2010: MITASTHME protocol — Role of mitochondria in the bronchial smooth muscle remodelling of asthmatic patients

• 2009: FIREBROB protocol — Role of fybrocytes in bronchial remodelling in COPD

• Interregional coordination (Bordeaux, Limoges, Toulouse) of the DIU (Inter-University Diploma) of Clinical Research Assistants and Clinical Research Technicians (FARC-TEC)

• Participation in the development of a remote learning and information platform on the proper use of medication for professionals and students — FORMeDOC — University of Bordeaux — Pilot project by the Collège National de Pharmacologie Médicale

• Set up of course in clinical research for state qualified nurses (IDE) and Clinical Research Technicians (TEC) — Centre de Formation Permanente des Personnels de Santé — University Hospital of Bordeaux

• Clinical trial modules in asthma and COPD — National week of DIU (Inter-University Diploma) Formation des investigateurs aux essais cliniques des médicaments (FIEC) - University of Paris VII

2024

• Jackson DJ, Heaney LG, Humbert M, Kent BD, Shavit A, Hiljemark L, Olinger L, Cohen D, Menzies-Gow A, Korn S; SHAMAL Investigators. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study. Lancet. 2024 Jan 20;403(10423):271-281. DOI:10.1016/S0140-6736(23)02284-5
•  Gueçamburu M, Zysman M. Place des biothérapies dans la BPCO [Biologic agents in COPD management]. Rev Mal Respir. 2024 Feb;41(2):127-138. French. DOI:10.1016/j.rmr.2023.11.003

2023

• Menzies-Gow A, Wechsler ME, Brightling CE, Korn S, Corren J, Israel E, Chupp G, Bednarczyk A, Ponnarambil S, Caveney S, Almqvist G, Gołąbek M, Simonsson L, Lawson K, Bowen K, Colice G; DESTINATION study investigators. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. Lancet Respir Med. 2023 May;11(5):425-438. DOI:10.1016/S2213-2600(22)00492-1
• Schlemmer F, Valentin S, Boyer L, Guillaumot A, Chabot F, Dupin C, Le Guen P, Lorillon G, Bergeron A, Basille D, Delomez J, Andrejak C, Bonnefoy V, Goussault H, Assié JB, Choinier P, Ruppert AM, Cadranel J, Mennitti MC, Roumila M, Colin C, Günther S, Sanchez O, Gille T, Sésé L, Uzunhan Y, Faure M, Patout M, Morelot-Panzini C, Laveneziana P, Zysman M, Blanchard E, Raherison-Semjen C, Giraud V, Giroux-Leprieur E, Habib S, Roche N, Dinh-Xuan AT, Sifaoui I, Brillet PY, Jung C, Boutin E, Layese R, Canoui-Poitrine F, Maitre B; RE2COVERI Study Group. Respiratory recovery trajectories after severe-to-critical COVID-19: a 1-year prospective multicentre study. Eur Respir J. 2023 Apr 1;61(4):2201532.  DOI:10.1183/13993003.01532-2022
• de Bruyn G, Wang J, Purvis A, Ruiz MS, Adhikarla H, Alvi S, Bonaparte MI, Brune D, Bueso A, Canter RM, Ceregido MA, Deshmukh S, Diemert D, Finn A, Forrat R, Fu B, Gallais J, Griffin P, Grillet MH, Haney O, Henderson JA, Koutsoukos M, Launay O, Torres FM, Masotti R, Michael NL, Park J, Rivera-Medina DM, Romanyak N, Rook C, Schuerman L, Sher LD, Tavares-Da-Silva F, Whittington A, Chicz RM, Gurunathan S, Savarino S, Sridhar S; VAT00002 booster cohorts study team. Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study. EClinicalMedicine. 2023 Jul 22;62:102109. DOI:10.1016/j.eclinm.2023.102109
• Louis R, Harrison TW, Chanez P, Menzella F, Philteos G, Cosio BG, Lugogo NL, de Luiz G, Burden A, Adlington T, Keeling N, Kwiatek J, Garcia Gil E; ANDHI Study Investigators. Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy. J Allergy Clin Immunol Pract. 2023 Jun;11(6):1759-1770.e7. DOI:10.1016/j.jaip.2023.03.009
• Chassagnon G, El Hajjam M, Boussouar S, Revel MP, Khoury R, Ghaye B, Bommart S, Lederlin M, Tran Ba S, De Margerie-Mellon C, Fournier L, Cassagnes L, Ohana M, Jalaber C, Dournes G, Cazeneuve N, Ferretti G, Talabard P, Donciu V, Canniff E, Debray MP, Crutzen B, Charriot J, Rabeau V, Khafagy P, Chocron R, Leonard Lorant I, Metairy L, Ruez-Lantuejoul L, Beaune S, Hausfater P, Truchot J, Khalil A, Penaloza A, Affole T, Brillet PY, Roy C, Pucheux J, Zbili J, Sanchez O, Porcher R; on the behalf of the French Society of Thoracic Imaging. Strategies to safely rule out pulmonary embolism in COVID-19 outpatients: a multicenter retrospective study. Eur Radiol. 2023 Aug;33(8):5540-5548. DOI:10.1007/s00330-023-09475-6
• Longuefosse A, Raoult J, Benlala I, Denis de Senneville B, Benkert T, Macey J, Bui S, Berger P, Ferretti G, Gaubert JY, Liberge R, Hutt A, Morel B, Laurent F, Baldacci F, Dournes G. Generating High-Resolution Synthetic CT from Lung MRI with Ultrashort Echo Times: Initial Evaluation in Cystic Fibrosis. Radiology. 2023 Jul;308(1):e230052. DOI:10.1148/radiol.230052
• Rosellini P, Girodet PO. STK11/LKB1 mutation in non-small cell lung cancer: Prognostic or predictive? FUNDAMENTAL & CLINICAL PHARMACOLOGY. 2023 Jun;37(1):50-51. Meeting Abstract: PM1-005

2022

• Beucher G, Blondot ML, Celle A, Pied N, Recordon-Pinson P, Esteves P, Faure M, Métifiot M, Lacomme S, Dacheux D, Robinson DR, Längst G, Beaufils F, Lafon ME, Berger P, Landry M, Malvy D, Trian T, Andreola ML, Wodrich H. Bronchial epithelia from adults and children: SARS-CoV-2 spread via syncytia formation and type III interferon infectivity restriction. Proc Natl Acad Sci U S A. 2022 Jul 12;119(28):e2202370119. DOI:10.1073/pnas.2202370119
• Hardt K, Vandebosch A, Sadoff J, Le Gars M, Truyers C, Lowson D, Van Dromme I, Vingerhoets J, Kamphuis T, Scheper G, Ruiz-Guiñazú J, Faust SN, Spinner CD, Schuitemaker H, Van Hoof J, Douoguih M, Struyf F; ENSEMBLE2 study group. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2022 Dec;22(12):1703-1715. DOI:10.1016/S1473-3099(22)00506-0
• BenlalaI, Dournes G, Girodet PO, Benkert T, Laurent F,Berger P. Evaluation of bronchial wall thickness in asthma using magnetic resonance imaging. Eur Respir J. 2021 Dec 31;59(1):2100329. DOI:10.1183/13993003.00329-2021
• Dournes G, Hall CS, Willmering MM, Brody AS, Macey J, Bui S, Denis de Senneville B, Berger P,Laurent F, Benlala I, Woods JC. Artificial intelligence in computed tomography for quantifying lung changes in the era of CFTR modulators. Eur Respir J. 2022 Mar 3;59(3):2100844. DOI:10.1183/13993003.00844-2021
• Rosellini P, Amintas S, Caumont C,Veillon R, Galland-Girodet S, Cuguillière A, Nguyen L, Domblides C, Gouverneur A, Merlio JP, Bezin J, Girodet PO. Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer. Eur J Cancer. 2022 Sep;172:85-95. DOI:10.1016/j.ejca.2022.05.026

• MOTOR study: Involvement of skeletal muscle fibrocytes in sarcOpenia in patients with chronic ObstRuctive bronchopneumopaThy
• ARNASA study: Phase 3, open-label extension study to assess the long-term safety of Astegolimab in patients with Chronic Obstructive Pulmonary Disease.
• EARCO study: An International Multi-Centre Observational Registry to Determine the Natural History of Patients with Alpha-1 Antitrypsin Deficiency
• TRINEXT study: Evaluation of the quality of life and characteristics of patients with chronic obstructive pulmonary disease (COPD) initiating treatment with the fixed triple therapy Beclometasone/Formoterol/Glycopyrronium DPI (Trimbow NEXThaler®) in real life.
• REVERT study: “Reversing airway remodeling with Tezepelumab”.
• BOA study: “Intragastric balloon in uncontrolled obese asthmatic patients: A controlled, randomized, multicenter study”.
• COPD-CARHE study: “Chronic airway disease, mucus rheology and exacerbations: a randomized controlled trial in COPD patients”
• TITANIA study: “Phase III multicenter, randomized, double-blind, parallel-group, placebo-controlled study evaluating the efficacy and safety of 2 chronic MEDI3506 regimens in patients with symptomatic COPD and a history of COPD exacerbations”.
• HIFAE study: “High-flow home oxygen therapy for the reduction of severe COPD exacerbations”.
• EO-DRIVE study: “Interest of corticosteroid therapy guided by blood eosinophilia in patients hospitalized for COPD exacerbation: a randomized, double-blind, controlled trial”.
• COBRA study: “Cohort on bronchial obstruction and asthma”: clinical-biological cohort follow-up coordinated at national level by Pr Patrick BERGER
• AERIFY II study: “Study to evaluate the efficacy, safety and tolerability of SAR440340/REGN3500/itepekimab in chronic obstructive pulmonary disease (COPD)”.
• BENRAMOD study: “Effect of benralizumab on airway remodeling in asthma”.
• ICONIC study: “Cohort study of incident chronic obstructive pulmonary disease”.

The CIC-P’s pulmonology department is currently looking for volunteers for various studies:

• 18+ subjects wanting to stop smoking

• 18+ subjects with severe asthma, non nonsmokers or who have stopped smoking for more than 3 years.

• 18+ subjects with COPD